Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2013, Article ID 976130, 5 pages
Review Article

Identification of Potential or Preclinical Cognitive Impairment and the Implications of Sophisticated Screening with Biomarkers and Cognitive Testing: Does It Really Matter?

Baycrest Centre for Geriatric Care, University of Toronto, 3560 Bathurst Street, Toronto, ON, Canada M6A 2E1

Received 2 April 2013; Revised 22 May 2013; Accepted 20 June 2013

Academic Editor: Annalena Venneri

Copyright © 2013 Michael Gordon. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Brown, “AUA Recommends against Routine Prostate Cancer Screening: New Recommendations More Closely Align With Those of AAFP, USPSTF: AAFP,” 2013, View at Google Scholar
  2. “1 in 3 seniors dies with dementia in U.S., The Associated Press,” 2013,
  3. “CTV Staff. Could the key to preventing the onset of Alzheimer's disease be in your feet?” 2013,
  4. V. Hauch, Getting Physical Can Cut the Risk of Alzheimer's, Toronto Star, Ontario, Canada, 2013.
  5. P. Belluck, Dementia Care Cost Is Projected to Double by 2040, New York Times, New York, NY, USA, 2013.
  6. M. Gordon, “The Cost of Dementia in the United States, HealthPlexus.Net,” 2013, View at Google Scholar
  7. S. Gauthier, C. Patterson, M. Gordon, J. Soucy, F. Schubert, and A. Leuzy, “Commentary on “Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.” A Canadian perspective,” Alzheimer's and Dementia, vol. 7, no. 3, pp. 330–332, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Gauthier, C. Patterson, H. Chertkow et al., “On behalf of the CCDTD4 participants. Recommendations of the 4th Canadian consensus conference on the diagnosis and treatment of dementia (CCCDTD4),” Canadian Geriatric Journal, vol. 15, no. 4, pp. 120–126, 2012. View at Google Scholar
  9. J. Tian, R. S. Bucks, J. Haworth, and G. Wilcock, “Neuropsychological prediction of conversion to dementia from questionable dementia: statistically significant but not yet clinically useful,” Journal of Neurology Neurosurgery and Psychiatry, vol. 74, no. 4, pp. 433–438, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Eckerström, E. Olsson, M. Bjerke et al., “A combination of neuropsychological, neuroimaging, and cerebrospinal fluid markers predicts conversion from mild cognitive impairment to dementia,” Journal of Alzheimer's Disease, 2013. View at Google Scholar
  11. J. A. Sonnen, K. S. Montine, J. F. Quinn, J. A. Kaye, J. C. Breitner, and T. J. Montine, “Biomarkers for cognitive impairment and dementia in elderly people,” The Lancet Neurology, vol. 7, no. 8, pp. 704–714, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Zhang and D. Shen, “Predicting future clinical changes of MCI patients using longitudinal and multimodal biomarkers,” PLoS ONE, vol. 7, no. 3, Article ID e33182, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Velayudhan, P. Proitsi, E. Westman et al., “Entorhinal cortex thickness predicts cognitive decline in Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 33, no. 3, pp. 755–766, 2013. View at Publisher · View at Google Scholar
  14. P. B. Gorelick, A. Scuteri, S. E. Black et al., “Vascular contributions to cognitive impairment and dementia: a statement for health care professionals from the American Heart Association/American Stroke Association,” Stroke, vol. 42, no. 9, pp. 2672–2713, 2011. View at Publisher · View at Google Scholar
  15. M. J. Valenzuela, F. E. Matthews, C. Brayne et al., “Multiple biological pathways link cognitive lifestyle to protection from dementia,” Biological Psychiatry, vol. 71, no. 9, pp. 783–791, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. S. M. Landau, S. M. Marks, E. C. Mormino et al., “Association of lifetime cognitive engagement and low β-amyloid deposition,” Archives of Neurology, vol. 69, no. 5, pp. 623–629, 2012. View at Publisher · View at Google Scholar
  17. A. Deslandes, “The biological clock keeps ticking, but exercise may turn it back,” Arquivos de Neuro-Psiquiatria, vol. 71, no. 2, pp. 113–118, 2013. View at Publisher · View at Google Scholar
  18. A. Rolfe and C. Burton, “Reassurance after diagnostic testing with a low pretest probability of serious disease: systematic review and meta-analysis,” JAMA Internal Medicine, vol. 173, no. 6, pp. 416–417, 2013. View at Publisher · View at Google Scholar
  19. Y. Y. Lim, K. A. Ellis, K. Harrington et al., “Use of the Cogstate Brief Battery in the assessment of Alzheimer's disease related cognitive impairment in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study,” Journal of Clinical and Experimental Neuropsychology, vol. 34, no. 4, pp. 345–358, 2012. View at Publisher · View at Google Scholar
  20. F. A. Huppert, C. Brayne, C. Gill, E. S. Paykel, and L. Beardsall, “CAMCOG—a concise neuropsychological test to assist dementia diagnosis: socio-demographic determinants in an elderly population sample,” British Journal of Clinical Psychology, vol. 34, no. 4, pp. 529–541, 1995. View at Google Scholar · View at Scopus
  21. “Cogstate bets big on its cognitive test Cognigram. BioSpectrum,” 2013,
  22. K. N. Nicholas and R. Katz, “Regulatory innovation and drug development for early-stage Alzheimer's disease,” The New England Journal of Medicine, vol. 368, pp. 1169–1171, 2013. View at Publisher · View at Google Scholar
  23. “MMSE,”
  24. “MOCA,”
  25. A. M. Clarfield, “The decreasing prevalence of reversible dementias: an updated meta-analysis,” Archives of Internal Medicine, vol. 163, no. 18, pp. 2219–2229, 2003. View at Publisher · View at Google Scholar